Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Staphylococcal Infections Medication

  • Author: Thomas E Herchline, MD; Chief Editor: Mark R Wallace, MD, FACP, FIDSA  more...
 
Updated: Apr 25, 2016
 

Medication Summary

Historically, isolates resistant to oxacillin (commonly referred to as methicillin-resistant S aureus [MRSA]) were resistant to most agents other than vancomycin, but these isolates were limited to nosocomial infections. More recently, many reports have described community-acquired MRSA infections that have been susceptible to various non–beta-lactam antibiotics. As such, patients with serious staphylococcal infections should be initially started on agents active against MRSA until susceptibility results are available. Many coagulase-negative staphylococci are oxacillin-resistant. The duration of treatment and the use of synergistic combinations depend on the type of infection encountered. Endocarditis due to S aureus may require a prolonged course of antibiotics.

Although many strains of MRSA that cause community-acquired infection are susceptible to trimethoprim-sulfamethoxazole, treatment with trimethoprim-sulfamethoxazole has been associated with clinical failure, especially in the presence of significant tissue damage.[29]

Vancomycin-resistant isolates have been reported; isolates with an increased minimum inhibitory concentration (MIC) to vancomycin are becoming more common and include both MRSA and methicillin-susceptible S aureus (MSSA).[30] Consensus guidelines recommend dosing vancomycin to avoid a trough of less than 10 mcg/mL; trough levels of 15-20 mcg/mL are recommended to treat complicated infections.[31]

In a study of 296 consecutive MRSA bacteremia episodes, several factors were predictive of high vancomycin MIC, including age older than 50 years, prior vancomycin exposure, history of MRSA bacteremia, history of chronic liver disease, and presence of a nontunneled catheter.[32]

Next

Antibiotics

Class Summary

Empiric antimicrobial therapy should be comprehensive and cover all likely pathogens in the context of the clinical setting.

Cefazolin

 

First-generation semisynthetic cephalosporin that arrests bacterial cell wall synthesis, inhibiting bacterial growth. Primarily active against skin flora, including S aureus (MSSA). Typically used alone for skin and skin-structure coverage. IV and IM dosing regimens are similar.

Ceftaroline (Teflaro)

 

Fifth-generation cephalosporin antimicrobial with activity against aerobic gram-negative bacteria, anaerobic gram-positive bacteria, and aerobic gram-positive bacteria, including MRSA.

Cefuroxime (Ceftin, Zinacef)

 

Second-generation cephalosporin with activity against respiratory aerobic gram-negative organisms, including Haemophilus influenza, and aerobic gram-positive aerobic organisms, including Streptococcus pyogenes and MSSA.

Dicloxacillin (Dycill, Dynapen)

 

Binds to one or more penicillin-binding proteins, which, in turn, inhibits synthesis of bacterial cell walls. For treatment of infections caused by penicillinase-producing staphylococci susceptible to methicillin (MSSA). Also active against most nonenterococcal streptococci. May use to initiate therapy when staphylococcal infection is suggested.

Nafcillin (Nallpen in Dextrose)

 

Preferred therapy for methicillin-susceptible S aureus (MSSA) staphylococci infections. Use parenteral therapy initially in severe infections. Oxacillin may be substituted for nafcillin based on hospital formulary. Change to oral therapy as condition warrants.

Dalbavancin (Dalvance)

 

Dalbavancin is a lipoglycopeptide antibiotic that prevents cross-linking by interfering with cell wall synthesis. It is bactericidal in vitro against Staphylococcus aureus and Streptococcus pyogenes at concentrations observed in humans at recommended doses. It is indicated for treatment of acute bacterial skin and skin structure infections caused by gram-positive bacteria including S aureus (including MSSA and MRSA ), S pyogenes, Streptococcus agalactiae, and the Streptococcus anginosus group (including S anginosus, S intermedius, S constellatus).

Oritavancin (Orbactiv)

 

Oritavancin is lipoglycopeptide antibiotic that inhibits cell wall biosynthesis and disrupts bacterial membrane integrity that leads to cell death. It is indicated for treatment of acute bacterial skin and skin structure infections caused by gram-positive bacteria including S aureus (including methicillin-susceptible S aureus and MRSA), S pyogenes, S agalactiae, S dysgalactiae, S anginosus group (S anginosus, S intermedius, S constellatus) and E faecalis (vancomycin-susceptible isolates only).

Telavancin (Vibativ)

 

Lipoglycopeptide antibiotic that is a synthetic derivative of vancomycin. Inhibits bacterial cell wall synthesis by interfering with polymerization and cross-linking of peptidoglycan. Unlike vancomycin, telavancin also depolarizes the bacterial cell membrane and disrupts its functional integrity. Indicated for complicated skin and skin structure infections caused by susceptible gram-positive bacteria, including Staphylococcus aureus (both methicillin-resistant and methicillin-susceptible strains), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group, and Enterococcus faecalis (vancomycin-susceptible isolates only).

Vancomycin

 

Indicated for patients who cannot receive penicillins and cephalosporins or have infections with resistant staphylococci. To lessen the risk for toxicity, assay vancomycin trough levels after third dose drawn 0.5 h prior to next dosing. Use CrCl to adjust dose in patients diagnosed with renal impairment.

Linezolid (Zyvox)

 

Prevents formation of functional 70S initiation complex, which is essential for bacterial translation process. Bacteriostatic against staphylococci (MSSA/MRSA).

The FDA warns against the concurrent use of linezolid with serotonergic psychiatric drugs, unless indicated for life-threatening or urgent conditions. Linezolid may increase serotonin CNS levels as a result of MAO-A inhibition, increasing the risk of serotonin syndrome.

Tedizolid (Sivextro)

 

Tedizolid is an oxazolidinone antibiotic indicated for skin and skin structure infections caused by susceptible isolates of Gram-positive bacteria including Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), Streptococcus pyogenes, S agalactiae, S anginosus Group (including S anginosus, S intermedius, and S constellatus), and Enterococcus faecalis. Its action is mediated by binding to the 50S subunit of the bacterial ribosome resulting in inhibition of protein synthesis.

Doxycycline (Acticlate, Adoxa, Vibramycin, Doryx)

 

Inhibits protein synthesis and thus bacterial growth by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria. Active against MSSA/MRSA. Less active against coagulase-negative staphylococci.

Minocycline (Minocin, Solodyn)

 

Inhibits protein synthesis and thus bacterial growth by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria. Active against MSSA/MRSA. Less active against coagulase-negative staphylococci. Doxycycline (Vibramycin) is used more commonly than minocycline.

Clindamycin (Cleocin)

 

Lincosamide for treatment of serious skin and soft tissue staphylococci infections. Also effective against aerobic and anaerobic streptococci (except enterococcal). Inhibits bacterial growth, possibly by blocking dissociation of peptidyl t-RNA from ribosomes, causing RNA-dependent protein synthesis to arrest.

Daptomycin (Cubicin)

 

Indicated to treat complicated skin and skin structure infections caused by S aureus (including MRSA strains), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, and Enterococcus faecalis. Also indicated for right-sided endocarditis due to S aureus. First of new antibiotic class called cyclic lipopeptides. Binds to bacterial membranes and causes rapid membrane potential depolarization, thereby inhibiting protein, DNA, and RNA synthesis and ultimately causing cell death.

Quinupristin/dalfopristin (Synercid)

 

Belongs to the streptogramin group of antibiotics. Mechanism of action is similar to macrolides/lincosamides. Inhibits protein synthesis and is usually bacteriostatic. Also an option for methicillin-resistant S aureus (MRSA) infections.

Tigecycline (Tygacil)

 

A glycylcycline antibiotic that is structurally similar to tetracycline antibiotics. Inhibits bacterial protein translation by binding to 30S ribosomal subunit, and blocks entry of amino-acyl tRNA molecules in ribosome A site. Indicated for complicated skin and skin structure infections and complicated intra-abdominal infections. Active against S aureus (including MRSA), as well as most streptococci, enterococci (including VRE), and gram-negative organisms (including anaerobes).

Trimethoprim-sulfamethoxazole (Bactrim, Bactrim DS, Sulfatrim Pediatric)

 

Inhibits bacterial growth by inhibiting synthesis of dihydrofolic acid. Active against most staphylococci (MSSA), including some strains resistant to methicillin (MRSA).

Previous
 
 
Contributor Information and Disclosures
Author

Thomas E Herchline, MD Professor of Medicine, Wright State University, Boonshoft School of Medicine; Medical Director, Public Health, Dayton and Montgomery County, Ohio

Thomas E Herchline, MD is a member of the following medical societies: Alpha Omega Alpha, Infectious Diseases Society of Ohio, Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

John L Brusch, MD, FACP Assistant Professor of Medicine, Harvard Medical School; Consulting Staff, Department of Medicine and Infectious Disease Service, Cambridge Health Alliance

John L Brusch, MD, FACP is a member of the following medical societies: American College of Physicians, Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Chief Editor

Mark R Wallace, MD, FACP, FIDSA Clinical Professor of Medicine, Florida State University College of Medicine; Clinical Professor of Medicine, University of Central Florida College of Medicine

Mark R Wallace, MD, FACP, FIDSA is a member of the following medical societies: American College of Physicians, American Medical Association, American Society for Microbiology, Infectious Diseases Society of America, International AIDS Society, Florida Infectious Diseases Society

Disclosure: Nothing to disclose.

Additional Contributors

Klaus-Dieter Lessnau, MD, FCCP Clinical Associate Professor of Medicine, New York University School of Medicine; Medical Director, Pulmonary Physiology Laboratory; Director of Research in Pulmonary Medicine, Department of Medicine, Section of Pulmonary Medicine, Lenox Hill Hospital

Klaus-Dieter Lessnau, MD, FCCP is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, American Medical Association, American Thoracic Society, Society of Critical Care Medicine

Disclosure: Nothing to disclose.

References
  1. Schramm GE, Johnson JA, Doherty JA, et al. Methicillin-resistant Staphylococcus aureus sterile-site infection: The importance of appropriate initial antimicrobial treatment. Crit Care Med. 2006 Aug. 34(8):2069-74. [Medline].

  2. Mermel LA, Farr BM, Sherertz RJ, et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis. 2001 May 1. 32(9):1249-72. [Medline].

  3. Simor AE, Phillips E, McGeer A, et al. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. Clin Infect Dis. 2007 Jan 15. 44(2):178-85. [Medline].

  4. Yamasaki O, Kaneko J, Morizane S, et al. The Association between Staphylococcus aureus strains carrying panton-valentine leukocidin genes and the development of deep-seated follicular infection. Clin Infect Dis. 2005 Feb 1. 40(3):381-5. [Medline].

  5. Labandeira-Rey M, Couzon F, Boisset S, Brown EL, Bes M, Benito Y. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science. 2007 Feb 23. 315(5815):1130-3. [Medline].

  6. Cremieux AC, Dumitrescu O, Lina G, Vallee C, et al. Panton-valentine leukocidin enhances the severity of community-associated methicillin-resistant Staphylococcus aureus rabbit osteomyelitis. PLoS One. 2009 Sep 25. 4(9):e7204. [Medline]. [Full Text].

  7. Nienaber JJ, Sharma Kuinkel BK, Clarke-Pearson M, Lamlertthon S, Park L, Rude TH, et al. Methicillin-Susceptible Staphylococcus aureus Endocarditis Isolates Are Associated With Clonal Complex 30 Genotype and a Distinct Repertoire of Enterotoxins and Adhesins. J Infect Dis. 2011 Sep. 204(5):704-713. [Medline]. [Full Text].

  8. Kleiner E, Monk AB, Archer GL, Forbes BA. Clinical significance of Staphylococcus lugdunensis isolated from routine cultures. Clin Infect Dis. 2010 Oct 1. 51(7):801-3. [Medline].

  9. von Eiff C, Becker K, Machka K, et al. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med. 2001 Jan 4. 344(1):11-6. [Medline].

  10. Mertz D, Frei R, Periat N, Zimmerli M, Battegay M, Flückiger U. Exclusive Staphylococcus aureus throat carriage: at-risk populations. Arch Intern Med. 2009 Jan 26. 169(2):172-8. [Medline].

  11. Gafter-Gvili A, Mansur N, Bivas A, et al. Thrombocytopenia in Staphylococcus aureus Bacteremia: Risk Factors and Prognostic Importance. Mayo Clin Proc. 2011 May. 86(5):389-96. [Medline]. [Full Text].

  12. Yilmaz M, Elaldi N, Balkan İİ, Arslan F, Batırel AA, Bakıcı MZ, et al. Mortality predictors of Staphylococcus aureus bacteremia: a prospective multicenter study. Ann Clin Microbiol Antimicrob. 2016 Feb 9. 15 (1):7. [Medline].

  13. McClelland RS, Fowler VG Jr, Sanders LL, et al. Staphylococcus aureus bacteremia among elderly vs younger adult patients: comparison of clinical features and mortality. Arch Intern Med. 1999 Jun 14. 159(11):1244-7. [Medline].

  14. Kravitz GR, Dries DJ, Peterson ML, et al. Purpura fulminans due to Staphylococcus aureus. Clin Infect Dis. 2005 Apr 1. 40(7):941-7. [Medline].

  15. Bor DH, Woolhandler S, Nardin R, Brusch J, Himmelstein DU. Infective endocarditis in the U.S., 1998-2009: a nationwide study. PLoS One. 2013. 8 (3):e60033. [Medline].

  16. Tande AJ, Palraj BR, Osmon DR, Berbari EF, Baddour LM, Lohse CM, et al. Clinical Presentation, Risk Factors, and Outcomes of Hematogenous Prosthetic Joint Infection in Patients with Staphylococcus aureus Bacteremia. Am J Med. 2016 Feb. 129 (2):221.e11-20. [Medline].

  17. Robicsek A, Beaumont JL, Paule SM, et al. Universal surveillance for methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals. Ann Intern Med. 2008 Mar 18. 148(6):409-18. [Medline].

  18. Bischoff WE, Wallis ML, Tucker BK, et al. "Gesundheit!" sneezing, common colds, allergies, and Staphylococcus aureus dispersion. J Infect Dis. 2006 Oct 15. 194(8):1119-26. [Medline].

  19. Diep BA, Chambers HF, Graber CJ, et al. Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med. 2008 Feb 19. 148(4):249-57. [Medline].

  20. Sing A, Tuschak C, Hörmansdorfer S. Methicillin-resistant Staphylococcus aureus in a family and its pet cat. N Engl J Med. 2008 Mar 13. 358(11):1200-1. [Medline].

  21. Deck MK, Anderson ES, Buckner RJ, Colasante G, Coull JM, Crystal B, et al. Multicenter Evaluation of the Staphylococcus QuickFISH Method for Simultaneous Identification of Staphylococcus aureus and Coagulase Negative Staphylococci Directly from Blood Culture Bottles in less than Thirty Minutes. J Clin Microbiol. 2012 Apr 4. [Medline].

  22. Sarikonda KV, Micek ST, Doherty JA, et al. Methicillin-resistant Staphylococcus aureus nasal colonization is a poor predictor of intensive care unit-acquired methicillin-resistant Staphylococcus aureus infections requiring antibiotic treatment. Crit Care Med. 2010 Oct. 38(10):1991-5. [Medline].

  23. Holland TL, Arnold C, Fowler VG Jr. Clinical management of Staphylococcus aureus bacteremia: a review. JAMA. 2014 Oct 1. 312 (13):1330-41. [Medline].

  24. Kaasch AJ, Fowler VG Jr, Rieg S, Peyerl-Hoffmann G, Birkholz H, Hellmich M, et al. Use of a simple criteria set for guiding echocardiography in nosocomial Staphylococcus aureus bacteremia. Clin Infect Dis. 2011 Jul 1. 53 (1):1-9. [Medline].

  25. Tubiana S, Duval X, Alla F, Selton-Suty C, Tattevin P, Delahaye F, et al. The VIRSTA score, a prediction score to estimate risk of infective endocarditis and determine priority for echocardiography in patients with Staphylococcus aureus bacteremia. J Infect. 2016 Feb 22. [Medline].

  26. Dumitrescu O, Boisset S, Badiou C, Bes M, Benito Y, Reverdy ME, et al. Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin. Antimicrob Agents Chemother. 2007 Apr. 51(4):1515-9. [Medline].

  27. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011 Feb. 52(3):e18-55. [Medline].

  28. Bai AD, Showler A, Burry L, Steinberg M, Ricciuto DR, Fernandes T, et al. Impact of Infectious Disease Consultation on Quality of Care, Mortality, and Length of Stay in Staphylococcus aureus Bacteremia: Results From a Large Multicenter Cohort Study. Clin Infect Dis. 2015 May 15. 60 (10):1451-61. [Medline].

  29. Proctor RA. Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis. Feb 15, 2008. 46(4):584-93. [Medline].

  30. Pillai SK, Wennersten C, Venkataraman L, Eliopoulos GM, Moellering RC, Karchmer AW. Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus. Clin Infect Dis. 2009 Oct 15. 49(8):1169-74. [Medline].

  31. [Guideline] Rybak MJ, Lomaestro BM, Rotscahfer JC, Moellering RC, Craig WA, Billeter M, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2009 Aug 1. 49(3):325-7. [Medline].

  32. Lubin AS, Snydman DR, Ruthazer R, Bide P, Golan Y. Predicting high vancomycin minimum inhibitory concentration in methicillin-resistant Staphylococcus aureus bloodstream infections. Clin Infect Dis. 2011 Apr 15. 52(8):997-1002. [Medline]. [Full Text].

  33. Jain R, Kralovic SM, Evans ME, et al. Veterans Affairs initiative to prevent methicillin-resistant Staphylococcus aureus infections. N Engl J Med. 2011 Apr 14. 364(15):1419-30. [Medline].

  34. Steed LL, Costello J, Lohia S, Jones T, Spannhake EW, Nguyen S. Reduction of nasal Staphylococcus aureus carriage in health care professionals by treatment with a nonantibiotic, alcohol-based nasal antiseptic. Am J Infect Control. 2014 Aug. 42(8):841-6. [Medline]. [Full Text].

  35. Archer GL. Staphylococcus aureus: a well-armed pathogen. Clin Infect Dis. 1998 May. 26(5):1179-81. [Medline].

  36. Baggett HC, Hennessy TW, Rudolph K, et al. Community-onset methicillin-resistant Staphylococcus aureus associated with antibiotic use and the cytotoxin Panton-Valentine leukocidin during a furunculosis outbreak in rural Alaska. J Infect Dis. 2004 May 1. 189(9):1565-73. [Medline].

  37. Begier EM, Frenette K, Barrett NL, et al. A high-morbidity outbreak of methicillin-resistant Staphylococcus aureus among players on a college football team, facilitated by cosmetic body shaving and turf burns. Clin Infect Dis. 2004 Nov 15. 39(10):1446-53. [Medline].

  38. Boggs W. Dicloxacillin for MSSA bacteremia tied to lower mortality than cefuroxime. Reuters Health Information. October 14, 2013. Available at http://www.medscape.com/viewarticle/81253. Accessed: October 22, 2013.

  39. Bouza E. New therapeutic choices for infections caused by methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2009. 15:44-52.

  40. Campbell KM, Vaughn AF, Russell KL, et al. Risk factors for community-associated methicillin-resistant Staphylococcus aureus infections in an outbreak of disease among military trainees in San Diego, California, in 2002. J Clin Microbiol. 2004 Sep. 42(9):4050-3. [Medline].

  41. Chang FY, MacDonald BB, Peacock JE, et al. A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore). 2003 Sep. 82(5):322-32. [Medline].

  42. Charlebois ED, Perdreau-Remington F, Kreiswirth B, et al. Origins of community strains of methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2004 Jul 1. 39(1):47-54. [Medline].

  43. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2003 Jan 1. 36(1):53-9. [Medline].

  44. Cunha BA. Antimicrobial therapy of multidrug-resistant Streptococcus pneumoniae, vancomycin-resistant enterococci, and methicillin-resistant Staphylococcus aureus. Med Clin North Am. 2006 Nov. 90(6):1165-82. [Medline].

  45. Cunha BA. Methicillin-resistant Staphylococcus aureus: clinical manifestations and antimicrobial therapy. Clin Microbiol Infect. 2005 Jul. 11 Suppl 4:33-42. [Medline].

  46. Cunha BA. Oral antibiotic therapy of serious systemic infections. Med Clin North Am. 2006 Nov. 90(6):1197-222. [Medline].

  47. Cunha BA. Staphylococcus aureus nosocomial pneumonia: Clinical aspects. Infect Dis Pract. 2007. 31:557-60.

  48. Cunha BA, Eisenstein LE, Hamid NS. Pacemaker-induced Staphylococcus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteremia from a coronary stent: Cure with prolonged/high-dose daptomycin without toxicity. Heart Lung. 2006 May-Jun. 35(3):207-11. [Medline].

  49. Cunha BA, Hamid N, Kessler H, Parchuri S. Daptomycin cure after cefazolin treatment failure of Methicillin-sensitive Staphylococcus aureus (MSSA) tricuspid valve acute bacterial endocarditis from a peripherally inserted central catheter (PICC) line. Heart Lung. 2005 Nov-Dec. 34(6):442-7. [Medline].

  50. Cunha BA, Mikail N, Eisenstein L. Persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia due to a linezolid "tolerant" strain. Heart Lung. 2008 Sep-Oct. 37(5):398-400. [Medline].

  51. Cunha BA, Pherez FM. Daptomycin resistance and treatment failure following vancomycin for methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE). Eur J Clin Microbiol Infect Dis. 2009 Jul. 28(7):831-3. [Medline].

  52. Czachor J, Herchline T. Bacteremic nonmenstrual staphylococcal toxic shock syndrome associated with enterotoxins A and C. Clin Infect Dis. 2001 Feb 1. 32(3):E53-6. [Medline].

  53. Daum RS, Ito T, Hiramatsu K, et al. A novel methicillin-resistance cassette in community-acquired methicillin-resistant Staphylococcus aureus isolates of diverse genetic backgrounds. J Infect Dis. 2002 Nov 1. 186(9):1344-7. [Medline].

  54. Deresinski S. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin Infect Dis. 2005 Feb 15. 40(4):562-73. [Medline].

  55. Fowler VG Jr, Sanders LL, Kong LK, et al. Infective endocarditis due to Staphylococcus aureus: 59 prospectively identified cases with follow-up. Clin Infect Dis. 1999 Jan. 28(1):106-14. [Medline].

  56. Fowler VG Jr, Sanders LL, Sexton DJ, et al. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis. 1998 Sep. 27(3):478-86. [Medline].

  57. Francis JS, Doherty MC, Lopatin U, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis. 2005 Jan 1. 40(1):100-7. [Medline].

  58. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med. 2005 Apr 7. 352(14):1436-44. [Medline].

  59. Grundmann H, Aires-de-Sousa M, Boyce J, Tiemersma E. Emergence and resurgence of methicillin-resistant Staphylococcus aureus as a public-health threat. Lancet. 2006 Sep 2. 368(9538):874-85. [Medline].

  60. Harbarth S, Liassine N, Dharan S, et al. Risk factors for persistent carriage of methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2000 Dec. 31(6):1380-5. [Medline].

  61. Herchline TE, Ayers LW. Occurrence of Staphylococcus lugdunensis in consecutive clinical cultures and relationship of isolation to infection. J Clin Microbiol. 1991 Mar. 29(3):419-21. [Medline].

  62. Herchline TE, Barnishan J, Ayers LW, et al. Penicillinase production and in vitro susceptibilities of Staphylococcus lugdunensis. Antimicrob Agents Chemother. 1990 Dec. 34(12):2434-5. [Medline].

  63. Jensen AG, Wachmann CH, Espersen F, et al. Treatment and outcome of Staphylococcus aureus bacteremia: a prospective study of 278 cases. Arch Intern Med. 2002 Jan 14. 162(1):25-32. [Medline].

  64. Kazakova SV, Hageman JC, Matava M, et al. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med. 2005 Feb 3. 352(5):468-75. [Medline].

  65. Kloos WE, Bannerman TL. Update on clinical significance of coagulase-negative staphylococci. Clin Microbiol Rev. 1994 Jan. 7(1):117-40. [Medline].

  66. Mekontso-Dessap A, Kirsch M, Brun-Buisson C, et al. Poststernotomy mediastinitis due to Staphylococcus aureus: comparison of methicillin-resistant and methicillin-susceptible cases. Clin Infect Dis. 2001 Mar 15. 32(6):877-83. [Medline].

  67. Miller LG, Diep BA. Clinical practice: colonization, fomites, and virulence: rethinking the pathogenesis of community-associated methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis. 2008 Mar 1. 46(5):752-60. [Medline].

  68. Mohan SS, McDermott BP, Cunha BA. Methicillin-resistant Staphylococcus aureus prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin. Heart Lung. 2005 Jan-Feb. 34(1):69-71. [Medline].

  69. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA. 2003 Dec 10. 290(22):2976-84. [Medline].

  70. Nouwen JL, Ott A, Kluytmans-Vandenbergh MF, et al. Predicting the Staphylococcus aureus nasal carrier state: derivation and validation of a "culture rule". Clin Infect Dis. 2004 Sep 15. 39(6):806-11. [Medline].

  71. Polenakovik H, Herchline T, Bacheller C, et al. Staphylococcus lugdunensis endocarditis after angiography. Mayo Clin Proc. 2000 Jun. 75(6):656-7. [Medline].

  72. Rasmussen JB, Knudsen JD, Arpi M, Schønheyder HC, Benfield T, Ostergaard C. Relative efficacy of cefuroxime versus dicloxacillin as definitive antimicrobial therapy in methicillin-susceptible Staphylococcus aureus bacteraemia: a propensity-score adjusted retrospective cohort study. J Antimicrob Chemother. 2013 Oct 3. [Medline].

  73. Saiman L, O'Keefe M, Graham PL 3rd, et al. Hospital transmission of community-acquired methicillin-resistant Staphylococcus aureus among postpartum women. Clin Infect Dis. 2003 Nov 15. 37(10):1313-9. [Medline].

  74. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med. 1999 Feb 18. 340(7):493-501. [Medline].

  75. US Food and Drug Administration. FDA Drug Safety Communication: Serious CNS reactions possible when linezolid (Zyvox®) is given to patients taking certain psychiatric medications. Available at http://www.fda.gov/Drugs/DrugSafety/ucm265305.htm. Accessed: July 27, 2011.

  76. Vandenesch F, Naimi T, Enright MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis. 2003 Aug. 9(8):978-84. [Medline].

 
Previous
Next
 
Embolic lesions in patient with Staphylococcus aureus endocarditis.
Close-up view of embolic lesions in patient with Staphylococcus aureus endocarditis.
Fifty-six-year-old man with erythema, edema, and drainage from below his right eye.
Gram stain in a 70-year-old woman with rheumatoid arthritis.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.